Review of Treatment and Prognosis of Stage IVB Cervical Carcinoma
Tomoka Usami et al. Int J Gynecol Cancer. 2016 Sep.
Abstract
Objectives: In most patients, stage IVB cervical cancer is incurable, and the outcomes are poor. There is significant individual variation in patients with stage IVB cervical cancer, in whom standard treatment has not been well defined. This study aims to review the outcomes and discuss treatment strategies in patients with stage IVB cervical cancer.
Methods: From January 1, 1992, to December 31, 2011, we retrospectively reviewed the data of patients with stage IVB cervical cancer who were given a diagnosis at the Department of Gynecology of the Cancer Institute Hospital.
Results: A total of 111 patients were enrolled. At the time of analysis, the median overall survival (OS) was 16.6 months (range, 0.2-120.9 months), and the 5-year OS rate was 20.2%. The 5-year OS rate was 59.4% for those with only para-aortic lymph node metastases; 24.8% for those with lymphogenous metastases, excluding those with only para-aortic lymph node metastases; 6.1% for those with hematogenous metastases; and 0% for those with disseminated metastases. The OS in patients with lymphogenous metastases was better compared with that of those with either hematogenous or disseminated metastases (P < 0.0001). In multivariate analysis, the performance status, site of metastases (only lymph node or other metastases), and local stage were all independent prognostic factors.
Conclusions: We determined performance status, site of metastases (only lymph node or other metastases), and local stage as independent prognostic factors in patients with stage IVB cervical cancer. Regarding treatment, we confirmed that the effectiveness of chemotherapy was also of significance.
Similar articles
Stage IVb thymic carcinoma: patients with lymph node metastases have better prognoses than those with hematogenous metastases.
Yang Y, Fan XW, Wang HB, Xu Y, Li DD, Wu KL. Yang Y, et al. BMC Cancer. 2017 Mar 27;17(1):217. doi: 10.1186/s12885-017-3228-2. BMC Cancer. 2017. PMID: 28347273 Free PMC article.
Special Focus on Stage IV Cervical Cancer Patients: A Decade Experience.
Espenel S, Garcia MA, Langrand-Escure J, Vallard A, Trone JC, Rancoule C, Vial N, Moreno-Acosta P, Chauleur C, Boutet C, Peoc Apos H M, Prevot-Bitot N, Guy JB, Magné N. Espenel S, et al. Oncology. 2019;97(3):125-134. doi: 10.1159/000500025. Epub 2019 Jul 2. Oncology. 2019. PMID: 31266037
Multi-center experience of robot-assisted laparoscopic para-aortic lymphadenectomy for staging of locally advanced cervical carcinoma.
Fastrez M, Goffin F, Vergote I, Vandromme J, Petit P, Leunen K, Degueldre M. Fastrez M, et al. Acta Obstet Gynecol Scand. 2013 Aug;92(8):895-901. doi: 10.1111/aogs.12150. Epub 2013 May 10. Acta Obstet Gynecol Scand. 2013. PMID: 23590725
[Metastatic mechanisms of uterine malignancies and therapeutic consequences].
Lax SF, Tamussino KF, Lang PF. Lax SF, et al. Pathologe. 2016 Nov;37(6):549-556. doi: 10.1007/s00292-016-0243-z. Pathologe. 2016. PMID: 27757531 Review. German.
Cited by
Survival, treatment pattern, and treatment outcome in patients with cervical cancer metastatic to distant lymph nodes.
Lin H, Wang D, Li H, Wu C, Zhang F, Lin Z, Yao T. Lin H, et al. Front Oncol. 2022 Aug 11;12:952480. doi: 10.3389/fonc.2022.952480. eCollection 2022. Front Oncol. 2022. PMID: 36033481 Free PMC article.
Score for the Overall Survival Probability of Patients With First-Diagnosed Distantly Metastatic Cervical Cancer: A Novel Nomogram-Based Risk Assessment System.
Zhang S, Wang X, Li Z, Wang W, Wang L. Zhang S, et al. Front Oncol. 2019 Nov 5;9:1106. doi: 10.3389/fonc.2019.01106. eCollection 2019. Front Oncol. 2019. PMID: 31750238 Free PMC article.
Efficacy of radical doses of pelvic radiotherapy for primary tumor treatment in patients with newly diagnosed organ metastatic cervical cancer.
Yin Z, Lou H, Tang H, Ni J, Zhou Q, Chen M. Yin Z, et al. Radiat Oncol. 2019 May 20;14(1):82. doi: 10.1186/s13014-019-1297-x. Radiat Oncol. 2019. PMID: 31109371 Free PMC article. Clinical Trial.
Detection of distant metastatic disease by positron emission tomography with 18F-fluorodeoxyglucose (FDG-PET) at initial staging of cervical carcinoma.
Lin A, Ma S, Dehdashti F, Markovina S, Schwarz J, Siegel B, Powell M, Grigsby P. Lin A, et al. Int J Gynecol Cancer. 2019 Mar;29(3):487-491. doi: 10.1136/ijgc-2018-000108. Epub 2019 Feb 9. Int J Gynecol Cancer. 2019. PMID: 30739082 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
- HighWire
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- International Agency for Research on Cancer - Screening Group
- MedlinePlus Consumer Health Information